Results 11 to 20 of about 38,942 (318)

Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation [PDF]

Ophthalmology and Therapy, 2021
Introduction To analyze the efficacy of biosimilar ranibizumab compared to innovator ranibizumab and bevacizumab. Methods We retrospectively analyzed consecutive patients treated with biosimilar ranibizumab for wet age-related macular degeneration (AMD ...
D. Ratra, K. Roy, Sneha Giridhar, Sushant Madaan, Pramod Muna Girish Parveen Rajiv Vikas Chetan S. Vinata G Bhende Bhende Rao Sen Raman Khetan Rao Pradeep Mur, P. Bhende, M. Bhende, G. Rao, P. Sen, R. Raman, V. Khetan, Chetan Rao, S. Pradeep, Vinata Muralidharan, G. Suganeswari, R. Roy, Debmalya Das, Suchetana Mukherjee, P. Rajesh, V. Jayaprakash, E. Nigam, C. Charanya, S. Sruthi, Maitreyi Chowdhury, Kalpita Das   +24 more
semanticscholar   +4 more sources

Ranibizumab for the treatment of diabetic retinopathy

Expert Opinion on Biological Therapy, 2021
Introduction: Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus and the leading cause of blindness in young adults.
I. Chatziralli
semanticscholar   +5 more sources

Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment

BMJ Open Ophthalmology, 2023
Topic This systematic review and meta-analysis provides a summary of the efficacy and safety of ranibizumab biosimilars relative to reference ranibizumab anti-vascular endothelial growth factor (VEGF) therapy for the treatment of neovascular age-related ...
Netan Choudhry, Amin Hatamnejad, Rohan Dadak, Samantha Orr, Charles Wykoff   +4 more
doaj   +2 more sources

Ranibizumab: A Review in Retinopathy of Prematurity

Pediatric Drugs, 2021
Ranibizumab (Lucentis®) is a monoclonal antibody fragment targeted against VEGF-A that is the first approved anti-VEGF agent for the treatment of retinopathy of prematurity (ROP). In the pivotal, randomized, phase III RAINBOW trial in infants with ROP, the majority of intravitreal ranibizumab recipients experienced treatment success at 24 weeks, with a
Arnold Lee, M. Shirley
semanticscholar   +4 more sources

The Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery

Drug Delivery, 2022
The Port Delivery System with ranibizumab (PDS) is an innovative intraocular drug delivery system designed for the continuous delivery of ranibizumab into the vitreous for 6 months and beyond.
Shrirang V. Ranade, Mark R. Wieland, Tammy Tam, Jennifer C. Rea, Judit Horvath, Aaron R. Hieb, Weitao Jia, Lori Grace, Giulio Barteselli, Jay M. Stewart   +9 more
doaj   +2 more sources

The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment-naïve patients

Scientific Reports, 2021
The ZIPANGU study assessed the efficacy and safety of ranibizumab as a one loading dose + pro re nata (one + PRN) regimen with/without focal/grid laser among treatment-naïve patients suffering from macular edema (ME) following branch retinal vein ...
Toshinori Murata, Mineo Kondo, Makoto Inoue, Shintaro Nakao, Rie Osaka, Chieko Shiragami, Kenji Sogawa, Akikazu Mochizuki, Rumiko Shiraga, Yohei Ohashi, Takeumi Kaneko, Chikatapu Chandrasekhar, Akitaka Tsujikawa, Motohiro Kamei   +13 more
doaj   +2 more sources

Potential Bias in Self-Controlled Case Series Design: Impact of Incident Versus Prevalent Scenarios of Exposure and Outcome. [PDF]

Pharmacoepidemiol Drug Saf
ABSTRACT Purpose To assess changes in study results in self‐controlled case series (SCCS) studies and explore potential biases when applying incident and prevalent exposure and outcome scenarios. Methods We used the National Health Insurance Service database in South Korea to conduct two SCCS studies: (1) the risk of retinal detachment following ...
Jung K, Byun SJ, Lim G, Lee JE, Lee H, Kim JH, Shin JY.   +6 more
europepmc   +2 more sources

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept

Medicina, 2023
Background and Objectives: Faricimab is the first intravitreal injection of vascular endothelial growth factor-A and angiopoietin-2 bispecific monoclonal antibody.
Hiromi Ohara, Y. Harada, Tomona Hiyama, Ayako Sadahide, Akira Minamoto, Yoshiaki Kiuchi   +5 more
semanticscholar   +1 more source

Role of ranibizumab in management of macular degeneration

Indian Journal of Ophthalmology, 2007
Age-related macular degeneration (AMD) is one of the most common causes of severe vision loss in the western world. Both animal and human studies have established that vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of this process.
Peter K. Kaiser, RishiP Singh
openalex   +4 more sources

Biomimetic, Injectable, and Self-Healing Hydrogels with Sustained Release of Ranibizumab to Treat Retinal Neovascularization.

ACS Applied Materials and Interfaces, 2023
Retinal neovascularization (RNV) is a typical feature of ischemic retinal diseases that can lead to traction retinal detachment and even blindness in patients, in which the vascular endothelial cell growth factor (VEGF) plays a pivotal role.
Ning Duan, Li Mei, Li-ting Hu, Xiaoni Yin, Xiangyang Wei, Y. Li, Qinghua Li, Guiqiu Zhao, Qihui Zhou, Zhaodong Du   +9 more
semanticscholar   +1 more source